(P-40) Impact of case and control selection on influenza vaccine effectiveness (VE) among adults aged 40 years and older hospitalized with acute respiratory illness (ARI) during 2022-2023 using a test negative design (TND): secondary analysis of the North America multi-specimen study

Senior Director
Pfizer
New York, New York, United States

Pfizer Inc.
Collegeville, Pennsylvania, United States

Chief Scientific Officer
Norton Healthcare
Louisville, Kentucky, United States

Dr.
Mt. Sinai Hospital
Toronto, Ontario, Canada

Norton Healthcare
Louisville, Kentucky, United States

Scientist
Sunnybrook Health Sciences Centre, University of Toronto
Toronto, Ontario, Canada

Clinical Scientist - Senior Manager
Pfizer
Champaign, Illinois, United States

Norton Healthcare
Louisville, Kentucky, United States

Clinical research manger
Sinai Health System, University of Toronto
Toronto, Ontario, Canada

Biostatistician
Norton Healthcare
Louisville, Kentucky, United States

Epidemiologist
Sinai Health System
Toronto, Ontario, Canada

Director, Infectious Diseases Clinical Program and Research
Norton Healthcare
Louisville, Kentucky, United States

Head, Microbiology
North York General Hospital
Toronto, Ontario, Canada

Chief of Microbiology
Norton Healthcare
Louisville, Kentucky, United States

Shared Health Laboratories
Toronto, Ontario, Canada

Pfizer
Collegeville, Pennsylvania, United States

Pfizer Canada
Toronto, Ontario, Canada

Vice President Global Medical Lead for Respiratory Vaccines
Pfizer Biopharma Group
Collegeville, Pennsylvania, United States

Senior Director, Scientific Affairs Lead, RSV Antiviral/Adult Vaccine Program
Pfizer Vaccines
Dublin, Dublin, Ireland